Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
Provided By GlobeNewswire
Last update: Apr 10, 2025
– Clinically Meaningful Efficacy Observed on Multiple Assessments –
– Confirmed Target Engagement with Reduced Iron Signal in MSA Affected Brain Regions –
Read more at globenewswire.comNASDAQ:ATHE (9/23/2025, 10:40:43 AM)
4.46
+0.03 (+0.68%)
Find more stocks in the Stock Screener
